{"id":57555,"date":"2024-07-11T05:12:26","date_gmt":"2024-07-11T03:12:26","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=57555"},"modified":"2024-07-11T05:12:26","modified_gmt":"2024-07-11T03:12:26","slug":"merck-podvadel-pri-klinickych-zkouskach-hpv-vakciny-lide-v-placebo-skupine-poskodil-hlinikovymi-adjuvanty","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2024\/07\/11\/merck-podvadel-pri-klinickych-zkouskach-hpv-vakciny-lide-v-placebo-skupine-poskodil-hlinikovymi-adjuvanty\/","title":{"rendered":"Merck podv\u00e1d\u011bl p\u0159i klinick\u00fdch zkou\u0161k\u00e1ch HPV vakc\u00edny: Lid\u00e9 v placebo skupin\u011b po\u0161kodil hlin\u00edkov\u00fdmi adjuvanty"},"content":{"rendered":"
<\/div>\n

Vakcina\u010dn\u00ed pr\u016fmysl p\u0159edst\u00edr\u00e1, \u017ee jeho v\u00fdtvory jsou bezpe\u010dn\u00e9. D\u011bl\u00e1 to t\u00edm zp\u016fsobem, \u017ee b\u011bhem klinick\u00fdch studi\u00ed nepou\u017e\u00edv\u00e1 skute\u010dn\u00e9 neaktivn\u00ed placebo.<\/span><\/p>\n

Nov\u00e1 studie publikovan\u00e1 v\u00a0<\/span>International Journal of Risk & Safety in Medicine<\/span><\/em>\u00a0(Mezim\u00e1rodn\u00ed \u017eurn\u00e1l rizik a bezpe\u010dnosti v medic\u00edn\u011b) zjistila, \u017ee spole\u010dnost Merck se v\u011bdom\u011b zapojila do v\u011bdeck\u00e9ho podvodu, kdy\u017e testovala svou HPV vakc\u00ednu proti papilom vir\u016fm na lidsk\u00fdch subjektech.<\/span><\/p>\n

Aby vakc\u00edna vypadala bezpe\u010dn\u011bji, ne\u017e ve skute\u010dnosti byla, spole\u010dnost Merck navrhla klinickou zkou\u0161ku s pou\u017eit\u00edm toxick\u00e9ho hlin\u00edkov\u00e9ho adjuvantu jako \u201eplaceba\u201c.<\/span><\/p>\n

N\u00e1vrh studie zav\u00e1d\u011bj\u00edc\u00edm zp\u016fsobem uv\u00e1d\u011bl, \u017ee jedna polovina \u00fa\u010dastn\u00edk\u016f obdr\u017e\u00ed aktivn\u00ed vakc\u00ednu, zat\u00edmco druh\u00e1 polovina obdr\u017e\u00ed placebo vakc\u00ednu (co\u017e znamen\u00e1 vakc\u00ednu bez \u00fa\u010dinn\u00e9 l\u00e1tky).<\/span><\/p>\n

Placebem pou\u017eit\u00fdm ve studii v\u0161ak nebyl neaktivn\u00ed fyziologick\u00fd roztok (slan\u00e1 voda), ale amorfn\u00ed hydroxyfosf\u00e1t s\u00edran hlinit\u00fd (AAHS). Takov\u00e9 \u201eplacebo\u201c m\u016f\u017ee u n\u011bkter\u00fdch lid\u00ed zp\u016fsobit v\u00e1\u017en\u00e9 alergick\u00e9 reakce.<\/span><\/p>\n

Ne\u017e\u00e1douc\u00ed reakce l\u00e1tky AAHS souvisej\u00ed s neurotoxick\u00fdmi \u00fa\u010dinky hlinit\u00e9 soli, kter\u00e9 zahrnuj\u00ed epilepsii a nep\u0159edv\u00eddateln\u00e9 neurologick\u00e9 a z\u00e1n\u011btliv\u00e9 reakce v cel\u00e9m t\u011ble.<\/span><\/p>\n

Vakc\u00edna proti HPV tak\u00e9 pou\u017e\u00edv\u00e1 hlin\u00edkov\u00fd adjuvant ke zv\u00fd\u0161en\u00ed sv\u00e9 \u00fa\u010dinnosti, ale hlin\u00edk ve skute\u010dnosti zp\u016fsobuje pouze z\u00e1n\u011bty a po\u0161kozen\u00ed mozku<\/span><\/h2>\n

\u00da\u010delem tohoto adjuvantu je zp\u016fsobit z\u00e1n\u011bt a p\u0159im\u011bt imunitn\u011b reaguj\u00edc\u00ed bu\u0148ky p\u0159ij\u00edt do m\u00edsta vpichu a vyvolat imunitn\u00ed odpov\u011b\u010f B-bun\u011bk (druh b\u00edl\u00fdch krvinek). Um\u011bl\u00e9 vyvol\u00e1n\u00ed z\u00e1n\u011btliv\u00e9 reakce je v\u0161ak dnes ji\u017e zastaral\u00e1 v\u011bda a je hlavn\u00edm d\u016fvodem v\u00fdskytu ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f po o\u010dkov\u00e1n\u00ed.<\/span><\/p>\n

Hlin\u00edkov\u00e9 soli se vychyt\u00e1vaj\u00ed v cytoplasm\u011b imunitn\u00edch bun\u011bk, jsou pak p\u0159en\u00e1\u0161eny p\u0159es krevn\u00ed ob\u011bh a n\u011bkdy p\u0159ech\u00e1zej\u00ed i p\u0159es hematoencefalickou bari\u00e9ru v mozku.<\/span><\/p>\n

Nakonec se ionty hlin\u00edku vyplav\u00ed na n\u011bjak\u00e9m m\u00edst\u011b v t\u011ble a zp\u016fsob\u00ed tam nep\u0159edv\u00eddateln\u00e9 po\u0161kozen\u00ed bun\u011bk. Mno\u017estv\u00ed hlin\u00edku v licencovan\u00fdch vakc\u00edn\u00e1ch se pohybuje od 0,125 do 0,85 mg v jedn\u00e9 d\u00e1vce.<\/span><\/p>\n

Pokud skupina \u00fa\u010dastn\u00edk\u016f studie s \u201eplacebem\u201c i skupina s aktivn\u00ed vakc\u00ednou proti HPV obsahuj\u00ed hlin\u00edkov\u00e9 adjuvanty, pak bude po\u010det ne\u017e\u00e1douc\u00edch reakc\u00ed podobn\u00fd pro ob\u011b skupiny. Rozd\u00edl v negativn\u00edch reakc\u00edch tak bude mezi skupinami men\u0161\u00ed.<\/span><\/p>\n

D\u00edky tomu se vakc\u00edna pak opticky jev\u00ed stejn\u011b bezpe\u010dn\u00e1, tedy srovnateln\u00e1 s \u201eplacebem\u201c \u2013 a\u010dkoli hlin\u00edkov\u00e9 adjuvanty p\u0159edstavuj\u00ed v\u00e1\u017en\u00e9 zdravotn\u00ed riziko bez ohledu na to, jak\u00fd antigen je s n\u00edm kombinov\u00e1n.<\/span><\/p>\n

Klinick\u00e9 zkou\u0161ky nutn\u011b uk\u00e1\u017e\u00ed, \u017ee \u201eplacebo\u201c i nov\u00e1 vakc\u00edna proti HPV sice zp\u016fsobuj\u00ed zdravotn\u00ed probl\u00e9my, ale po\u010det zdravotn\u00edch probl\u00e9m\u016f je p\u0159ibli\u017en\u011b stejn\u00fd. Farmaceutick\u00e9 firma na z\u00e1klad\u011b toho prohl\u00e1s\u00ed, \u017ee vakc\u00edna vyvol\u00e1v\u00e1 m\u00e9n\u011b ne\u017e\u00e1douc\u00edch reakci ne\u017e ve skute\u010dnosti vyvol\u00e1v\u00e1.<\/span><\/p>\n

Tento klamav\u00fd \u00fadaj umo\u017e\u0148uje st\u00e1tn\u00edm regula\u010dn\u00edm org\u00e1n\u016fm schv\u00e1lit vakc\u00ednu na trh bez skute\u010dn\u00e9ho v\u011bdeck\u00e9ho pochopen\u00ed nebezpe\u010d\u00ed hlin\u00edkov\u00fdch adjuvant\u016f a jin\u00fdch slo\u017eek t\u00e9to vakc\u00edny.<\/span><\/p>\n

Kdy\u017e se v klinick\u00fdch zkou\u0161k\u00e1ch pou\u017e\u00edv\u00e1 hlin\u00edk jako placebo, pak pro vakc\u00edny nelze mluvit o \u201ezlat\u00e9m standardu\u201c<\/span><\/h2>\n

Klinick\u00e9 zkou\u0161ky vakc\u00edn proti HPV nejsou \u201ezlat\u00fdm standardem\u201c. Pro za\u010d\u00e1tek, \u00fa\u010dastn\u00edci studie nebyli \u0159\u00e1dn\u011b informov\u00e1ni o povaze studie a rizic\u00edch spojen\u00fdch s fale\u0161n\u00fdm placebem.<\/span><\/p>\n

\u00da\u010dastn\u00edci byli informov\u00e1ni, \u017ee placebo pou\u017eit\u00e9 v testech bude bu\u010f fyziologick\u00fd roztok, nebo neaktivn\u00ed l\u00e1tka, co\u017e je standardn\u00ed praxe v klinick\u00fdch zkou\u0161k\u00e1ch pro stanoven\u00ed z\u00e1kladn\u00ed linie pro porovn\u00e1v\u00e1n\u00ed.<\/span><\/p>\n

Av\u0161ak \u201eplacebo\u201c bylo ve skute\u010dnosti adjuvant s obsahem hlin\u00edku, kter\u00fd zvy\u0161uje imunitn\u00ed odpov\u011b\u010f a potenci\u00e1ln\u011b m\u016f\u017ee zp\u016fsobit nep\u0159\u00edzniv\u00e9 \u00fa\u010dinky.<\/span><\/p>\n

Za prv\u00e9, tento podvod neumo\u017enil \u00fa\u010dastn\u00edk\u016fm studie u\u010dinit pln\u011b informovan\u00e1 rozhodnut\u00ed.<\/span><\/p>\n

Za druh\u00e9, \u00fa\u010dastn\u00edci, kte\u0159\u00ed byli n\u00e1hodn\u011b p\u0159id\u011bleni do \u201eplacebo\u201c skupiny s hlin\u00edkov\u00fdm adjuvantem, byli vystaveni zbyte\u010dn\u00fdm rizik\u016fm a tato rizika pomohla zamaskovat rizika vakc\u00edny proti HPV.<\/span><\/p>\n

Pou\u017eit\u00ed aktivn\u00edho adjuvantu jako placeba nevytvo\u0159il skute\u010dn\u00fd z\u00e1klad pro porovn\u00e1v\u00e1n\u00ed a mohlo zakr\u00fdt skute\u010dn\u00e9 obavy t\u00fdkaj\u00edc\u00ed se bezpe\u010dnosti samotn\u00e9 vakc\u00edny.<\/span><\/p>\n

Takov\u00e9 fale\u0161n\u00e9 klinick\u00e9 zkou\u0161ky jsou poru\u0161en\u00edm l\u00e9ka\u0159sk\u00e9 etiky, kter\u00e1 vy\u017eaduje minimalizaci \u0161kod a zaji\u0161t\u011bn\u00ed toho, aby \u00fa\u010dastn\u00edci m\u011bli p\u0159esn\u00e9 informace pro poskytnut\u00ed sv\u00e9ho informovan\u00e9ho souhlasu.<\/span><\/p>\n

A kone\u010dn\u011b, pou\u017eit\u00ed reaktivn\u00edho placeba, jako je hlin\u00edkov\u00fd adjuvant, mohlo b\u00fdt spole\u010dnost\u00ed Merck od\u016fvodn\u011bno pro potenci\u00e1ln\u00ed zv\u00fd\u0161en\u00ed imunogenicity testovan\u00e9 vakc\u00edny.<\/span><\/p>\n

Etick\u00e9 obavy spo\u010d\u00edvaj\u00ed v tom, \u017ee tento v\u00fdb\u011br placeba mohl ohrozit schopnost v\u011bdc\u016f p\u0159esn\u011b posoudit bezpe\u010dnostn\u00ed profil vakc\u00edny t\u00edm, \u017ee se smazal rozd\u00edl mezi ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky souvisej\u00edc\u00edmi s vakc\u00ednou a t\u011bmi, kter\u00e9 zp\u016fsobilo placebo.<\/span><\/p>\n

Ani hlin\u00edkov\u00fd adjuvant, ani HPV vakc\u00edna nebyly \u0159\u00e1dn\u011b vyhodnoceny z hlediska bezpe\u010dnosti, co\u017e by m\u011blo vzbudit regula\u010dn\u00ed obavy t\u00fdkaj\u00edc\u00ed se n\u00e1vrhu testovac\u00edch protokol\u016f a dodr\u017eov\u00e1n\u00ed etick\u00fdch v\u011bdeck\u00fdch sm\u011brnic spole\u010dnost\u00ed Merck.<\/span><\/p>\n

Z\u00e1v\u011br<\/span><\/h2>\n

Od uveden\u00ed HPV vakc\u00edny spole\u010dnosti Merck na trh se vyskytlo n\u011bkolik p\u0159\u00edpad\u016f syndromu postur\u00e1ln\u00ed ortostatick\u00e9 tachykardie (POTS) charakterizovan\u00e9ho abnorm\u00e1ln\u00ed reakc\u00ed to\u010den\u00ed hlavy, rozmazan\u00e9ho vid\u011bn\u00ed a\u00a0<\/span>z\u00e1vrat\u00ed<\/span><\/a>\u00a0p\u0159i p\u0159echodu do vzp\u0159\u00edmen\u00e9 polohy.<\/span><\/p>\n

Neurologick\u00e9 symptomy se mnohdy zhor\u0161uj\u00ed a mohou u \u010dlov\u011bka vyvolat dokonce trval\u00e9 po\u0161kozen\u00ed a invaliditu. V\u011bt\u0161inu ob\u011bt\u00ed (85%) tvo\u0159\u00ed mlad\u00e9 dosp\u00edvaj\u00edc\u00ed d\u00edvky, kter\u00fdm je sl\u00edben\u00e1 ochrana p\u0159ed rakovinou d\u011blo\u017en\u00edho \u010d\u00edpku, ale nakonec skon\u010d\u00ed s v\u00e1\u017en\u00fdm zdravotn\u00edm posti\u017een\u00edm.<\/span><\/p>\n

A nejhor\u0161\u00ed na tom cel\u00e9m je, \u017ee tuto podvodem schv\u00e1lenou vakc\u00ednu za\u010dalo Slovensko pln\u011b propl\u00e1cet pro d\u00edvky i chlapce ve v\u011bku 12 a\u017e 15 let! Pokud m\u00e1te p\u0159\u00e1tele a zn\u00e1m\u00e9 s d\u011btmi v tomto v\u011bkov\u00e9m rozmez\u00ed, ur\u010dit\u011b je p\u0159ed touto vakc\u00ednou varujte!<\/span><\/p>\n

Autor: Lance D. Johnson, Zdroj:\u00a0<\/span>naturalnews.com<\/span><\/a><\/p>\n

\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Vakcina\u010dn\u00ed pr\u016fmysl p\u0159edst\u00edr\u00e1, \u017ee jeho v\u00fdtvory jsou bezpe\u010dn\u00e9. D\u011bl\u00e1 to t\u00edm zp\u016fsobem, \u017ee b\u011bhem klinick\u00fdch…<\/p>\n","protected":false},"author":2,"featured_media":57556,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[940,2135,651,21],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/57555"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=57555"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/57555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/57556"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=57555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=57555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=57555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}